For much of the 20th century, asbestos was seen as an industrial hero. Its ability to resist heat, fire, and corrosion made it a go-to material for construction, manufacturing, and even consumer products like baby powder. However, what was once hailed as a “miracle material” eventually became one of the most feared environmental hazards due to its links to several types of cancer. While the evidence is clear when it comes to asbestos causing diseases like mesothelioma and lung cancer, its potential role in ovarian cancer is much more controversial. Can asbestos really cause this gynecologic malignancy? That is the central question explored in the scientific review “Asbestos and ovarian cancer: examining the historical evidence”, published in the International Journal of Gynecological Cancer.
This issue resurfaced in the public spotlight when Johnson & Johnson withdrew its talc-based baby powder from the North American market after thousands of lawsuits claimed it had caused ovarian cancer in women. The concern stems from the possibility that the talc was contaminated with asbestos. While talc and asbestos share some mineral similarities, only asbestos has been classified by the International Agency for Research on Cancer (IARC) as causally linked to ovarian cancer. But how strong is the evidence supporting this claim?
Asbestos refers to a group of naturally occurring silicate minerals composed of microscopic fibers, which are categorized into two major families: serpentine and amphibole. The most widely used form is chrysotile (white asbestos), though crocidolite (blue asbestos) is considered the most carcinogenic. These fibers, once inhaled or ingested, can remain in the body for decades, potentially triggering chronic inflammation and cellular damage. In the case of mesothelioma, the evidence is overwhelming: asbestos can induce genetic mutations, generate reactive oxygen species, inhibit programmed cell death (apoptosis), and activate signaling pathways associated with tumor growth. However, when it comes to ovarian cancer, the proposed mechanisms are still speculative and not well supported by experimental data.
In vitro studies and animal models have shown that certain types of asbestos fibers can trigger inflammatory responses in ovarian epithelial cells, increasing the production of interleukin 13 and other growth factors. Some studies also reported activation of anti-apoptotic pathways similar to those observed in mesothelioma. Interestingly, not all animal species respond the same way. In one IARC-cited study, asbestos was injected into the peritoneal cavity of four mammal species, and only rabbits and guinea pigs developed ovarian epithelial changes resembling early-stage human tumors. This suggests that hormonal or anatomical factors may play a role, but the findings alone are insufficient to establish a causal link.
A major challenge in this discussion is the diagnostic overlap between ovarian cancer and peritoneal mesothelioma. For decades, these two diseases were often confused in medical records and death certificates, as they share similar histological features. In fact, until 1999 there was no specific ICD code for mesothelioma. This introduces a significant classification bias in retrospective studies. Even in older cohort studies—such as those analyzing women who worked in gas mask factories during World War II—misdiagnosis rates reached up to 33%, with cases originally classified as ovarian cancer later confirmed to be mesothelioma. Such a high margin of diagnostic error can dramatically distort epidemiological conclusions.
Despite these limitations, the IARC in 2012 concluded that there is a clear causal link between asbestos and ovarian cancer. This conclusion was primarily based on five cohort studies involving women with occupational exposure to asbestos. However, these studies have notable weaknesses. Several of them lacked any pathological review of tumor samples. In the study by Wignall and Fox, only three out of 500 cases were reviewed, and one of them turned out to be mesothelioma misclassified as ovarian cancer. Additionally, most of these studies predate the use of modern immunohistochemical tools like PAX-8, which is now a standard marker for distinguishing ovarian from mesothelial tumors. Even the meta-analysis cited by the IARC found that when only studies with rigorous pathological review were considered, the link between asbestos and ovarian cancer was no longer statistically significant.
Another key issue is inconsistency among findings. While some studies showed a modest increase in ovarian cancer risk among exposed women, others—such as a large Finnish cohort of over 5,000 women—found no significant association at all. Some studies even reported concurrent increases in uterine cancer rates, which is puzzling since there is no clear evidence linking asbestos to uterine malignancies.
Figure 1. Asbestos fibers from industrial or talc sources may enter the body and reach the ovaries, where they can induce oxidative stress, inflammation, and genetic mutations, potentially contributing to ovarian cancer development.
So what can we conclude from all this? While there is an observable statistical association between asbestos exposure and ovarian cancer in some studies, this association is weak, inconsistent, and highly vulnerable to diagnostic error. In the absence of experimental data (which would be unethical to obtain) and with an unclear biological mechanism, it is not scientifically rigorous to assert a causal link. At the same time, the possibility cannot be entirely dismissed. What is needed is more robust research, using modern pathology techniques, well-characterized patient cohorts, and better control of confounding variables.
In summary, Slomovitz and colleagues urge caution in how we interpret historical epidemiological data and stress the critical importance of diagnostic accuracy when studying environmental carcinogens. In the case of asbestos and ovarian cancer, the scientific story is still unfolding. We owe it to public health, legal integrity, and scientific credibility to continue investigating this question with the best tools and standards available.
Main Reference:
Slomovitz B, de Haydu C, Taub M, Coleman RL, Monk BJ. Asbestos and ovarian cancer: examining the historical evidence. Int J Gynecol Cancer. 2021 Jan;31(1):122-128. doi: 10.1136/ijgc-2020-001672. Epub 2020 Oct 9. PMID: 33037108.
Other References:
Furuya S, Chimed-Ochir O, Takahashi K, David A, Takala J. Global Asbestos Disaster. Int J Environ Res Public Health. 2018 May 16;15(5):1000. doi: 10.3390/ijerph15051000. PMID: 29772681; PMCID: PMC5982039.
Dyer O. Jury awards $4.7bn damages against Johnson & Johnson in talcum cancer case. BMJ. 2018 Jul 16;362:k3135. doi: 10.1136/bmj.k3135. PMID: 30012582.
Slomovitz, B., De Haydu, C., Taub, M., Coleman, R. L., & Monk, B. J. (2021). Asbestos and ovarian cancer: examining the historical evidence. International journal of gynecological cancer, 31(1), 122-128.
